16th World Clinical Biomarkers and Companion Diagnostics Summit The Westin Boston Seaport District, Boston

As regulatory headwinds turn to tailwinds, precision medicine is shifting into a new gear.

Evolving FDA approaches to LDTs and 510(k) pathways are removing long-standing friction, coordinated Rx-Dx launches are gaining pace, ctDNA and MRD are advancing as clinically meaningful endpoints, and reimbursement expansion is improving access to high-value genomic testing. At the same time, innovation in multiplex assays, multi-omics platforms, liquid biopsy, digital pathology, spatial biology, and AI-powered diagnostics, are rapidly reshaping the IVD landscape.

Fueled by $60B+ in diagnostic deal-making and strategic partnerships, the 16th World Clinical Biomarkers and Companion Diagnostics Summit returns as the industry’s esteemed end-to-end precision medicine forum. Convening 850+ senior leaders from biopharma, diagnostic, regulatory, healthcare, testing labs and multimodal communities, this meeting will span the full value chain; from biomarker discovery to clinical validation, approval and real-world adoption, across a diverse range of technologies and disease areas.

Now expanded into five focused content tracks, join us in harnessing the speed, scale, and growing complexity of innovation happening in next-generation IVD platforms, multimodal data, and CDx development.